How to Build and Sell a Biotech in 2024
Strategic Alternatives
Investor Priorities in Biotech Acquisitions
Exploring the focus of investors on de-risked assets with high upside potential in biotech companies, emphasizing aspects like market timeline, revenue generation, and asset value. The episode wraps up by inviting listeners to connect with RBC Capital Markets for more insights and discussions.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
